Table 3.
List of drugs and their targets currently undergoing clinical trials for MPN and/or PTCL disease as mono- and/or combination therapies as of October 2017 (https://clinicaltrials.gov/). Drugs that are involved in clinical trials for both MPN and PTCL are highlighted in italic. Only targeted therapy drugs are listed (no chemotherapy or immunotherapy drugs included).
| MPN |
PTCL |
||
|---|---|---|---|
| Drug | Target | Drug | Target |
| Ruxolitinib | JAK1/2 | Ruxolitinib | JAK1/2 |
| Momelotinib | Cerdulatinib | SYK/JAK | |
| Itacitinib | JAK1 | ASN002 | |
| NS-018 | JAK2 | Everolimus | mTOR/AKT pathway |
| Pacritinib | Temsirolimus | ||
| LY2784544 | BMS-906024 | Notch | |
| Umbralisib (TGR-1202) | PI3Kδ | LY3039478 | |
| Idelalisib | Tipifarnib | Ras (posttranslational modification) | |
| INCB050465 | Umbralisib (TGR-1202) | PI3Kδ | |
| Rigosertib | PI3K and PLK pathways | CPI-618 | α-ketoglutarate dehydrogenase |
| Glasdegib (PF-04449913) | Sonic hedgehog pathway | Alisertib | Aurora A kinase |
| Sonidegib (LDE225) | DS-3201b | EZH2 | |
| LCL161 | cIAP1 and cIAP2 | Decitabine | Hypomethylation |
| Idasanutlin (RG7388) | TP53–MDM2 | Panobinostat | Pan-HDAC |
| PRIMA-1MET (APR-246) | TP53 | Romidepsin | |
| IMG-7289 | LSD1 | Belinostat | |
| Givinostat (ITF2357) | Class I and class II HDACs | AR-42 | |
| Panobinostat | Pan-HDAC | Chidamide | |
| Azacitidine | Hypomethylation | Bortezomib | Proteasome |
| Decitabine | Carfilzomib | ||
| PU-H71 | HSP90 | Ixazomib (MLN 9708) | |
| AUY922 | |||